Changes to the CDC Adult Immunization Schedule for 2020
Note: “Those with a history of Guillain–Barré syndrome within 6 weeks of a previous dose of influenza vaccine generally should not be vaccinated, unless vaccination benefits outweigh risks for those at higher risk for severe complications from influenza.”
Note: Any person who is not at risk for hepatitis A virus infection but wants protection against it may be vaccinated
Catch-up HPV vaccination (not adequately vaccinated previously)
Public health benefit of HPV vaccinations for adults in this age range is minimal, yet some persons who are not adequately vaccinated might benefit. HPV vaccination does not need to be discussed with most adults older than 26 years of age, but clinicians can consider discussing HPV vaccination with persons who are most likely to benefit. HPV vaccines are not licensed for use in adults older than age 45 years.
Recommended Adult Immunization Schedule, United States, 2020
In October 2017, the FDA approved and ACIP recommended a Shingrix (RZV) vaccine for adults ≥50 years of age. Zostavax (ZVL) is no longer available for use in the United States, as of November 18, 2020.
Shingrix is recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged ≥50 years
Adverse Events
CDC: Shingles (Herpes Zoster) Vaccination Information for Healthcare Providers
Please log in to ObGFirst to access this page